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Edited by Francesc PosasAbstract Phosphatidylinositol 5-phosphate (PtdIns5P) is a rel-
atively recently discovered inositol lipid whose metabolism and
functions are not yet clearly understood. We have transfected
cells with a number of enzymes that are potentially implicated
in the synthesis or metabolism of PtdIns5P, or subjected cells
to a variety of stimuli, and then measured cellular PtdIns5P lev-
els by a speciﬁc mass assay. Stable or transient overexpression of
Type IIa PtdInsP kinase, or transient overexpression of Type Ia
or IIb PtdInsP kinases caused no signiﬁcant change in cellular
PtdIns5P levels. Similarly, subjecting cells to oxidative stress
or EGF stimulation had no signiﬁcant eﬀect on PtdIns5P, but
stimulation of HeLa cells with a phosphoinositide-speciﬁc
PLC-coupled agonist, histamine, caused a 40% decrease within
1 min. Our data question the degree to which inositide kinases
regulate PtdIns5P levels in cells, and we discuss the possibility
that a signiﬁcant part of both the synthesis and removal of
this lipid may be regulated by phosphatases and possibly
phospholipases.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Mass assay1. Introduction
The polyphosphoinositol lipids are now recognised to be a
diverse family of compounds with a wide range of physiologi-
cal functions [1,2]. The most recent of these lipids to be discov-
ered, phosphatidylinositol 5-phosphate (PtdIns5P) [3], is the
favoured substrate for Type II PtdInsP kinases (Type II PIP-
kins) [3], and it has been suggested to have several intracellular
functions, including the stimulation of inositol lipid phospha-
tases such as myotubularin [4], PTEN [5], or an unidentiﬁed
PtdIns(3,4,5)P3 5-phosphatase [6]. PtdIns5P has also been sug-Abbreviations: PtdIns5P, phosphatidylinositol 5-phosphate; PtdIns-
(4,5)P2, phosphatidylinositol (4,5)-bisphosphate; PIPkin, PtdInsP
kinase
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doi:10.1016/j.febslet.2005.04.027gested to regulate actin polymerization [7], and the activity of
the candidate tumour suppressor protein ING-2 [8].
PtdIns5P is present constitutively within cells, but its levels
are subject to acute regulation: PtdIns5P levels increase in
platelets stimulated by thrombin [9], in insulin-stimulated adi-
pocytes [7] and, within the nucleus, at G1 in the cell cycle [10].
Furthermore, levels decrease in osmotically shocked adipo-
cytes or ﬁbroblasts [11]. At present, the mechanism underlying
these dynamic changes is not understood, and indeed the phys-
iological pathways by which PtdIns5P is synthesised and
catabolised are themselves unclear. Two classes of inositol li-
pid kinase, the Type I and Type III PIPkins, can generate
PtdIns5P from the inositol lipid PtdIns in vitro [12,13], but
in neither case is it clear whether this constitutes a physiolog-
ical mechanism for PtdIns5P production. Although overex-
pression of PIKfyve, the mammalian Type III PIPkin,
increases cellular PtdIns5Plevels by about 80% in 3T3L1
adipocytes [11,12], it is not certain if this is by direct synthesis
or by catabolism of PtdIns(3,5)P2, the probable major product
of PIKfyve. Signiﬁcantly, phosphoinositide 3-phosphatases of
the myotubularin family also increase PtdIns5Plevels when
transfected into cells [4,13], suggesting that the observed eﬀects
of PIKfyve transfection on PtdIns5P may indeed be indirect.
Similarly, the major physiological role of the Type I PIPkins
is the synthesis of the multi-functional inositol lipid phospha-
tidylinositol (4,5)-bisphosphate (PtdIns(4,5)P2). Whether or
not they also regulate PtdIns5P levels in vivo remains to be
determined.
Mechanisms for the removal of PtdIns5P are also incom-
pletely understood. It has previously been suggested that an
important function of Type II PIPkins is to control levels of
PtdIns5P by phosphorylating it to PtdIns(4,5)P2 [1,3]. Nuclear
levels of PtdIns5P can be regulated in this way [8] by overex-
pression of the predominantly nuclear [14] Type IIb PIPkin,
but it remains open as to the extent to which Type II PIPkins
regulate PtdIns5P at normal expression levels. Recently, an
alternative route of PtdIns5P catabolism has been suggested
by the discovery of an apparently PtdIns5P-speciﬁc phospha-
tase [15], but again the signiﬁcance of this protein in regulating
PtdIns5P levels remains to be determined.
In the work presented here, we have sought to increase
understanding of PtdIns5P by using the mass assay we devel-
oped previously [9] to measure PtdIns5P in cells subjected to
a variety of stimuli, or transfected with a range of enzymes that
have been implicated in PtdIns5P metabolism. Our data throw
new light on some of the previous suggestions that have beenblished by Elsevier B.V. All rights reserved.
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enigmatic lipid.2. Materials and methods
2.1. Materials
PtdIns5P was from Echelon. Anti-p38 MAP kinase antibody was
from Cell Signalling Technology, as was an antibody speciﬁc for the
Thr180/Tyr182 phosphorylated form of p38 MAP kinase. The general
anti-phosphotyrosine antibody was clone 4G 10 from Upstate. Con-
structs for GFP-tagged PIPkin IIa and IIb were as in Ciruela et al.
[14]. The construct for GFP-Type Ia PIPkin (using the mouse nomen-
clature) was as in [16], and a kinase-dead construct (see [17]) was a gift
from Dr. M.L. Giudici. Pharbin, an inositide 5-phosphatase [18,19],
was cloned out of the original pYX-Asc vector from an IMAGE clone
(BC052717) into the FLAG tagged vector pCMVTag 2A (Stratagene)
and into the GFP vector pEGFPC2 (Clontech).
2.2. Cell biology
HeLa and Cos-7 cells were cultured in Dulbeccos modiﬁed Eagles
Medium with 10% FCS in 5% CO2. Cos-7 cells were transfected with
FuGENE 6 transfection reagent (Boehringer); plasmid cDNAs were
prepared using an endotoxin-free Maxi-prep kit (Qiagen). HeLa cells
were transfected using calcium phosphate precipitation [16,17]. HeLa
cells stably transfected with human Type IIa PIPkin were made using
a commercial TET-On system (Clontech), though it was found that the
line created had lost its tetracycline inducibility, so they were used di-
rectly as a stably transfected line (see Fig. 1).Fig. 1. (A) Stable transfection of HeLa cells. The parent HeLa cells
(), and a clone stably transfected with Type IIa PIPkin used in the
experiments included in Table 1 (+), were Western blotted with a
monoclonal antibody to Type II PIPkins [30,31]. Arrow indicates the
position of Type IIa PIPkin. Type II PIPkin immunoreactivity can be
demonstrated in anti-Type II PIPkin immunoprecipitates from paren-
tal HeLa cells (KAH, unpublished), but the levels of the endogenous
protein are too low to produce a signal in the conditions used in this
blot. (B) Stimulation of HeLa cells with EGF. Anti-phosphotyrosine
Western blot of HeLa cells in the presence (E) and absence (C) of a 5-
min stimulus with EGF. The position of the EGF receptor is shown by
the arrow. Samples of these cells were analysed for PtdIns5P content
(Table 2). (C) Treatment with H2O2. HeLa cells were incubated with
(+) or without () 600 lM H2O2 for an hour, and the degree of
phosphorylation of p38 MAP kinase determined by Western blotting
with an anti-phospho-(Thr180/Tyr 182) p38 MAP kinase antibody (b).
Total p38 MAP kinase content is shown in (a). Samples of these cells
were analysed for PtdIns5P content (Table 2). Positions of molecular
weight markers (in kDa) are indicated.2.3. Lipid extraction
Cells grown on 10 mm dishes had their medium removed, 1 ml ice
cold 5% PCA was added to the dishes and the cells were scraped with
a rubber policeman. The PCA extraction was removed to an Eppen-
dorf tube on ice and the dish washed with a further 1 ml 5% PCA,
which was pooled with the ﬁrst extraction. Samples were spun at
5000 · g for 10 min at 4 C and the supernatant removed from the pel-
let. Lipids were then extracted from the pellet using acidiﬁed chloro-
form/methanol as in Morris et al. [9]. Before loading onto neomycin
beads (see below), an aliquot was taken for total phospholipid mea-
surement [20] so that PtdIns5P mass could be standardised relative
to cellular phospholipid.
2.4. PtdIns5P mass assay
This also followed the procedure of Morris et al. [9], but with some
minor alterations in loading and eluting the neomycin beads to im-
prove reproducibility. 50 ll of a 50% suspension of neomycin beads
[21,22] was pipetted into a glass microtube, and washed successively
in 500 ll, of 5:10:2 (by volume) CHCl3:CH3OH:H2O, 5:10:2 (by vol-
ume) CHCl3:CH3OH:ammonium formate (0.5 M ﬁnal concentration
of formate), then 5:10:2 (by volume) CHCl3:CH3OH:H2O and ﬁnally
resuspended with 50 ll 5:10:2 (by volume) CHCl3:MeOH:ammonium
formate (ﬁnal concentration 50 mM formate [22]). The lipids extracted
from the tissue (above) were dried down, resuspended in a volume of
500 ll of 5:10:2 (by volume) CHCl3:CH3OH:ammonium formate (ﬁnal
concentration 50 mM formate) and added to the beads. The samples
were then incubated at room temperature for 20 min, spun at
4000 · g for 1 min and the supernatant was discarded. The beads were
washed twice with 500 ll 50 mM formate buﬀer with the last residue
taken oﬀ with a Hamilton syringe. The lipids were eluted twice with
2 M triethylbicarbonate (TEAB) [9] to which phosphatidylserine had
been added to a ﬁnal concentration of 14.25 lM; this acts as an inert
carrier and also acts as a carrier in the PIPkin assay (below). The beads
were ﬁrst incubated with 250 ll 2 M TEAB + phosphatidylserine for
an hour, spun for 2 min at 4000 · g and the supernatant removed to
a plastic microfuge tube using a Hamilton syringe. The beads were fur-
ther washed with 100 ll 2 M TEAB + phosphatidylserine (also for
1 h), and the supernatant was combined with the ﬁrst. The tubes were
placed in a vacuum centrifuge overnight at 60 C.
Lipid phosphorylation with recombinant Type IIa PIPkin was as in
[9]. Phosphorylation was initiated by addition of 2 lCi [c-32P] ATP and
5 lM ATP to each tube, and extraction and separation of the
PtdIns(4,5)P2 product by thin layer chromatography was exactly as de-
scribed previously [9]. PtdIns5P mass levels were determined with ref-
erence to a standard curve constructed in each individual experiment,
using known amounts of synthetic PtdIns5P, and expressed relative to
the amount of total cellular phospholipid present in each sample.
There was some minor variability in mass levels between experiments,
so the results are expressed as percentages of the control levels deter-
mined in each individual experiment.
2.5. Veriﬁcation of assay speciﬁcity
In selected samples, the reliability of the assay was tested as previ-
ously described [9], to ensure that the PtdIns5P measurements were
accurate. Brieﬂy, the Ins(1,4,5)P3 headgroup of the PtdIns(4,5)P2 ob-
tained in the radiolabelling step was chemically cleaved from the lipid
and then dephosphorylated using recombinant Type I inositol 5-phos-
phatase. Separation of the products by hplc conﬁrmed that more than
95% of the original lipid was radiolabelled at the D4 position (that is,
95% of the radiolabel released from Ins(1,4,5)P3 by the 5-phosphatase
was in Ins(1,4)P2, and the rest was in inorganic phosphate), conﬁrming
that the assay is a reliable measurement of PtdIns5P levels. However,
in one experimental protocol this procedure demonstrated that this
was not so (see results), and the signiﬁcance of this ﬁnding is discussed
below.3. Results and discussion
3.1. PtdIns5P levels
The amount of PtdIns5P in unstimulatedHeLa cells and Cos-
7 cells was 302.14 ± 34.5 (S.E.M.; n = 20) and 223.3 ± 23.9
2870 H.F. Roberts et al. / FEBS Letters 579 (2005) 2868–2872(S.E.M.; n = 10) pmol/lmol cellular phospholipid, respectively.
If we assume that approximately 10% of cellular phospholipid
content is inositol lipids, then overall the amount of PtdIns5P
can be estimated as 0.2–0.3% of the inositol lipids in these cells,
in good agreement with previous studies [3,11].
3.2. Eﬀect of PIPkin transfection on PtdIns5P levels
As discussed above, it is possible that Type II PIPkins regu-
late PtdIns5P levels by phosphorylating PtdIns5P to
PtdIns(4,5)P2. To investigate this possibility, HeLa cells were
stably transfected with type IIa PIPkin (Fig. 1A) and the
impact on PtdIns5P levels determined. Somewhat surprisingly,
despite the expression of considerable type IIa PIPkin
immunoreactivity (Fig. 1A), there was no detectable diﬀerence
in PtdIns5P levels between these cells and the parent cell line
(Table 1). This might be due to adaptation of the cells to the
chronic high expression levels of the enzyme (that is, an
increased removal of PtdIns5P could be compensated for by
increased synthesis). As a control for this, we also acutely
transfected Cos-7 cells (to a 50–60% eﬃciency) with GFP-
tagged Type IIa PIPkin, an approach that should decrease
(though it cannot eliminate) the likelihood of a compensatory
upregulation of synthesis. However, acute transfection also
had no detectable eﬀect on PtdIns5P levels (Table 1).
We also tested Type IIb PIPkin in similar experiments. As
discussed in Section 1, this is primarily a nuclear isoform
[14], though as it was originally cloned from its association
with a cell surface receptor [23], it is also likely to have a sig-
niﬁcant cytoplasmic component. Overexpression of Type IIb
PIPkin in Cos7 cells was similarly without detectable eﬀect
on cellular PtdIns5P levels (Table 1). This assay measures
the PtdIns5P content of the whole cell, and does not discrimi-
nate between pools within the nucleus or elsewhere, but this re-
sult suggests that the inability of Type IIa PIPkin to aﬀect total
PtdIns5P levels (above) was not simply due to its inability to
obtain access to a large nuclear pool of the lipid.
Although this lack of eﬀect of Type II PIPkin transfection
could be explained by the PIPkins not having access to the
bulk of the cellular PtdIns5P due to compartmentalization, it
is still likely that they can access any PtdIns5P pools available
to the endogenous enzymes. Thus the failure of their marked
overexpression to make an impact on the levels of PtdIns5PTable 1














(n = 8; 2 expts)
N.S.
Type IIb PIPkin 85.6 ± 8.8
(n = 12; 3 expts)
N.S.
Type Ia PIPkin 122.7 ± 29
(n = 8; 2 expts)
N.S.
Data show the PtdIns5P levels for HeLa cells stably transfected with
Type IIa PIPkin (see Section 2 and Fig. 1A), or for Cos-7 cells were
transfected for 24 h with the constructs indicated. In all acute trans-
fections the eﬃciency was conﬁrmed by immunocytochemistry to be
50–60% (not shown). Results are expressed as percentage controls
(these are either GFP-transfected cells, or for the Type Ia PIPkin, cells
transfected with a kinase-dead Type Ia PIPkin construct).strongly suggests that these enzymes do not contribute to the
regulation of resting PtdIns5P levels in the cell lines examined.
This observation in turn calls into question the idea that a
principal function of Type II PIPkins is to regulate cellular
PtdIns5P levels.
As Type I PIPkins have also been reported to synthesise
PtdIns5P from PtdIns in vitro [24], we also investigated
whether transfection with one of these enzymes might increase
PtdIns5P in intact cells. Note that for these experiments we
used as a control cells transfected with a kinase-dead mutant
with less than 1% of wild-type activity, to circumvent artefacts
caused by high levels of Type I PIPkin transfection (see e.g.
[17]). However, transfection of Type Ia PIPkin into Cos-7 cells
produced no detectable diﬀerence in PtdIns5P levels (Table 1).
This ﬁnding suggests that the Type I PIPkins are not responsi-
ble for regulating cellular PtdIns5P levels.3.3. Role of phosphatases in PtdIns5P production
These generally negative results with kinases led us to con-
sider the contribution of inositol lipid phosphatases to regulat-
ing PtdIns5P levels. It is already known that the lipid
phosphatase myotubularin and its homologues can produce
PtdIns5P via the hydrolysis of PtdIns(3,5)P2 [13]. Further-
more, the bacterial lipid phosphatase IpgD generates large
amounts of PtdIns5P when introduced into vertebrate cells,
by hydrolysing PtdIns(4,5)P2 [25]. Whilst no mammalian
orthologue of that activity has been identiﬁed, a number of
PtdIns(4,5)P2 5-phosphatases are found in the human genome.
The possibility that a PtdIns(4,5)P2 5-phosphatase might also
generate PtdIns5P physiologically is one that has not been con-
sidered, even though Rameh et al. [3] showed that one member
of the 5-phosphatase family, SHIP-1, does have signiﬁcant
(about 5%) 4-phosphatase action on PtdIns(4,5)P2 in vitro.
To investigate this possibility, we transfected Cos7 cells with
another inositol lipid 5-phosphatase, Pharbin ([18], also cloned
by Kong et al. [19]). Pharbin appeared signiﬁcantly to increase
PtdIns5Plevels as measured by the mass assay. However,
following the assay we analysed the PtdIns(4,5)P2 that was
generated in vitro by removing its headgroup and dephospho-
rylating it with Type I inositol polyphosphate phosphatase (see
Section 2). This analysis revealed that there was considerable
incorporation of radiolabel into the D5 position (not shown),
which means that PtdIns4P in the extract from the Pharbin-
transfected cells was making a signiﬁcant contribution as a
substrate. This assay relies crucially on the high preference
of the Type II PIPkins for PtdIns5P over PtdIns4P, such that
even though there is much more PtdIns4P in cells than
PtdIns5P, the assay is still speciﬁc for the latter [9]. But it is
important to note that the enzyme will also phosphorylate
PtdIns4P in vitro if provided with very high levels of this lipid
[3,9]. We conclude that, in this set of experiments, the assay
was compromised because it was detecting a huge increase in
cellular PtdIns4P engendered by the 5-phosphatase action of
Pharbin on cellular PtdIns(4,5)P2. This ﬁnding highlights
directly the limitations of the PtdIns5P assay when PtdIns4P
levels are very high, and it emphasises the need to check the as-
says veracity by analysing the distribution of radioactivity in
the PtdIns(4,5)P2 between the 4 and 5 phosphates whenever
PtdIns5Plevels appear to increase.
Overall, the kinase expression data do not support the idea
that PtdIns5P levels are regulated by inositol lipid kinases.
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inant route of PtdIns5P production in cells is via dephospho-
rylation of a more highly phosphorylated inositol lipid
(PtdIns(3,5)P2, PtdIns(4,5)P2 or both – see above and Section
1). A further piece of evidence that supports this conclusion
lies in the observation that PtdInsP substrates prepared from
mammalian brains that have been removed, chilled and pro-
cessed within approximately 1 h post-mortem contain lower
levels of PtdIns5P than those from brains processed less rap-
idly (R.F.I. and A.J.L. unpublished observations). PtdIns5P
generated post-mortem is most likely to result from phospha-
tase rather than from kinase activity, and this suggests that
such phosphatases are able to make signiﬁcant contributions
to PtdIns5P content. These observations, together with the re-
cent discovery of a speciﬁc PtdIns5P phosphatase [15], suggest
that phosphatases may be more important than kinases in the
regulation of PtdIns5P levels in vivo.
3.4. Eﬀects of cellular stimuli on PtdIns5P levels
As mentioned above, a number of stimuli are reported to
cause ﬂuctuations in cellular PtdIns5P levels. To identify fur-
ther treatments that also modify PtdIns5P levels, HeLa cells
were subjected to a number of diverse stimuli, and the eﬀects
(if any) on PtdIns5P levels measured. The results are presented
in Table 2. Stimulation with epidermal growth factor (EGF) at
a concentration that stimulated tyrosine phosphorylation of
the EGF receptor (Fig. 1B) had no signiﬁcant eﬀect on
PtdIns5P levels (Table 2). Similarly, oxidative stress (600 lM
hydrogen peroxide, applied for 1 h, conditions which pro-
moted robust phosphorylation of p38 MAP kinase: Fig. 1C)
was without eﬀect on PtdIns5P content (Table 2).
However, stimulation with histamine produced a signiﬁcant
decrease in PtdIns5P levels (Table 2). In HeLa cells, histamine
activates PtdIns(4,5)P2 breakdown via the activation of phos-
pholipase C [26]. We conﬁrmed, using Fura-2, that our HeLa
cells gave a robust Ca2+ signal in response to histamine within
30 s (not shown). To determine whether the observed eﬀect
(Table 2) was due to activation of protein kinase C (PKC)
downstream of PLC activation, we tested the eﬀects of theTable 2






EGF 90.3 ± 25.2
(n = 7; 2 expts)
N.S.
H2O2 88.3 ± 27.4
(n = 8; 2 expts)
N.S.
Histamine 62.5 ± 1.7
(n = 11; 3 expts)
P < 0.05
Thapsigargin 93.7 ± 10.8
(n = 8; 2 expts)
N.S.
Phorbol ester 71.7 ± 10.8
(n = 8; 2 expts)
N.S.
Histamine + chelerythrine 48.4 ± 6.9
(n = 4; 1 expt)
P < 0.05
HeLa cells were stimulated as described and PtdIns5P levels measured.
All data are expressed as % control cells in the same individual
experiment. Treatments used were: EGF, 5 min; H2O2, 600 lM for
60 min; histamine, 100 lM for 1 min; thapsigargin, 1 lM 1 min; TPA,
1 mg/ml for 1 min; histamine + chelerythine, 30 min pre-treatment
with 10 lM chelerythrine, then 100 lM histamine for 1 min.phorbol ester TPA on PtdIns5P levels, and of the PKC inhib-
itor chelerythrine on the histamine-induced change. TPA pro-
duced a small (though non-signiﬁcant) reduction in PtdIns5P
levels (Table 2), but the inability of the PKC inhibitor to pre-
vent the eﬀect of histamine treatment on PtdIns5P levels (Ta-
ble 2) suggests that PKC activation is not required for the
observed decrease. Furthermore, thapsigargin was also with-
out eﬀect (Table 2), suggesting that the elevation of cytosolic
free Ca2+ concentration provoked by histamine receptor acti-
vation is also not involved in regulating PtdIns5P levels.
The eﬀects of histamine on HeLa cells are apparently all
mediated via H1 receptor-stimulated PI-PLC activation [27],
so the simplest (though not the only) remaining explanation
of these results is the possibility that they are due to direct
hydrolysis of PtdIns5P by activated PI-PLC. The structure of
PI-PLC suggests that PtdIns5P could act as a substrate [28],
and indeed PLC d1 has been shown to catalyse the breakdown
of PtdIns5P in vitro [29]. The possible physiological conse-
quences of such a signalling pathway are unclear, however, if
PLC-mediated PtdIns5P hydrolysis does underlie the observed
eﬀect of histamine on PtdIns5P levels in HeLa cells, the extent
of the eﬀect suggests that at least 40% of the total cellular
PtdIns5P is found in a plasma membrane pool accessible to
PLC.
Whatever the explanation, the ﬁnding that a stimulus that
activates PLC leads to a rapid decrease in PtdIns5P levels in
HeLa cells is somewhat surprising, given our earlier demon-
stration that thrombin stimulation of platelets, which causes
a marked activation of platelet PLC, leads to an increase in
PtdIns5P levels [9]. We cannot presently account for this diﬀer-
ence, though it is interesting to note that the increase seen with
thrombin was signiﬁcantly delayed relative to the known time-
course of PLC activation [9]. It is possible that, in platelets,
stimulation also causes a marked increase in PtdIns5P produc-
tion that may mask the eﬀects of early PtdIns5P hydrolysis,
but this suggestion remains speculative.4. Conclusions
In conclusion, we have demonstrated that overexpressing
Type I or Type II PIPkins does not signiﬁcantly aﬀect
PtdIns5P levels in Cos-7 or HeLa cells, supporting the idea
that lipid phosphatase activity is perhaps more likely to be
of major importance in regulating levels of this lipid mediator.
Furthermore, we have shown that stimulation of HeLa cells
with histamine provokes a marked decrease in PtdIns5P levels,
though whether this reduction results from phosphatase or
from phospholipase activation remains to be established.
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